Rafael Amado Sells 3,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Rafael Amado sold 3,000 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $38.41, for a total value of $115,230.00. Following the completion of the sale, the insider now directly owns 30,834 shares of the company’s stock, valued at approximately $1,184,333.94. This trade represents a 8.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Rafael Amado also recently made the following trade(s):

• On Tuesday, December 31st, Rafael Amado sold 7,583 shares of Zai Lab stock. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24.

Zai Lab Trading Down 1.8 %

NASDAQ:ZLAB opened at $37.33 on Friday. Zai Lab Limited has a twelve month low of $13.48 and a twelve month high of $39.61. The company has a market capitalization of $4.09 billion, a P/E ratio of -13.48 and a beta of 1.08. The firm has a 50-day moving average price of $30.51 and a two-hundred day moving average price of $27.59.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The business had revenue of $109.07 million for the quarter, compared to analysts’ expectations of $110.15 million. On average, equities research analysts predict that Zai Lab Limited will post -2.58 earnings per share for the current year.

Hedge Funds Weigh In On Zai Lab

Institutional investors have recently made changes to their positions in the stock. FMR LLC increased its position in Zai Lab by 749.1% during the 4th quarter. FMR LLC now owns 5,475,505 shares of the company’s stock worth $143,403,000 after purchasing an additional 4,830,646 shares in the last quarter. RTW Investments LP acquired a new stake in shares of Zai Lab during the 4th quarter worth about $65,714,000. Janus Henderson Group PLC grew its holdings in shares of Zai Lab by 34.2% during the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock worth $211,488,000 after buying an additional 2,232,507 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of Zai Lab in the fourth quarter valued at approximately $46,172,000. Finally, Wellington Management Group LLP lifted its stake in shares of Zai Lab by 18.4% during the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock valued at $203,660,000 after buying an additional 1,312,115 shares during the period. 41.65% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ZLAB. Scotiabank began coverage on shares of Zai Lab in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 target price for the company. JPMorgan Chase & Co. upped their price target on Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Bank of America reiterated a “neutral” rating and set a $36.10 target price (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.